Navigation Links
Sevelamer in Medical News

Nephrologists Indicate High Interest in AMAG Pharmaceuticals' Newly Approved Feraheme According to Latest BioTrends Report

...ge over Amgen's Aranesp on "minimal hassles with prior authorizations" and "adequate reimbursement". In the phosphate binder market, Genzyme's sevelamer compounds are being used to treat almost half of the dialysis patients. At one year post launch, virtually all Nephrologists have started to use Renv...

Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group

... hemodialysis patients on Renvela compared to 67% in the previous quarter. sevelamer is the market leader in dialysis with 55% share. Among CKD patients, sevelamer and FMC's PhosLo each have approximately 36% market share. In both the dia...

Cutting Phosphate May Protect Kidney Patients From Heart Trouble

.... Food and Drug Administration recently decided to extend the label of phosphate-binding drugs on the market. These drugs -- calcium acetate (PhosLo), sevelamer (Renagel) and lanthanum carbonate (Fosrenol) -- will now be labeled to indicate they are approved for treatment of high serum phosphate levels in CKD...

Readily available treatment could help prevent heart disease in kidney patients

...dy and others like it, the Food and Drug Administration has recently decided to extend the label of such drugs. As a result, calcium acetate (PhosLo), sevelamer (Renagel) and lanthanum carbonate (Fosrenol) will be labeled to indicate they are approved for treatment of high serum phosphate levels in patients wi...

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year

...$1.24 billion this year, compared with $1.13 billion in 2007. -- Sales of sevelamer therapies Renagel(R) (sevelamer hydrochloride) and Renvela(R) (sevelame... sNDA for this indication. A CKD indication will expand the market for sevelamer and help sustain the long-term growth of the Renal franchise. -- Sale...
Sevelamer in Medical Technology

Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate

CAMBRIDGE, Mass., June 18, 2007 /PRNewswire-FirstCall/ -- Genzyme Corp. today announced the results of two new studies comparing a powder form of Renvela (sevelamer carbonate) to Renagel tablets (sevelamer hydrochloride), including one trial in which patients received the powder form three times p...

Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate

CAMBRIDGE, Mass., June 18, 2007 - Genzyme Corp. (Nasdaq: GENZ) today announced the results of two new studies comparing a powder form of Renvela™ (sevelamer carbonate) to Renagel® tablets (sevelamer hydrochloride), including one trial in which patients received the powder form three time...

Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease

...nounced today represent one portion of a comprehensive clinical program for sevelamer carbonate. Data showing the equivalence of sevelamer carbonate and sevelamer hydrochloride were presented last week at the sprin...
Sevelamer in Biological Technology

Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients

...sules per day of calcium acetate, calcium carbonate, lanthanum carbonate or sevelamer hydrochloride or any combination of these agents were eligible for enrollme...sules per day of calcium acetate, calcium carbonate, lanthanum carbonate or sevelamer hydrochloride or any combination of these agents were eligible for enrollme...

ChartTrends(R): Bone and Mineral Metabolism in Dialysis Reveals Latest Trends in the Treatment of Calcium, Phosphorus and PTH

...ted data, combination binder therapy is prescribed infrequently. Genzyme's sevelamer is the market share leader despite the fact that it has the highest pill bu... lower persistency compared to Renagel, Tums and FMC's PhosLo. Within the sevelamer franchise, patient conversion to Renvela stands at about 27% and about half...

BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...Genzyme's Renvela in Q108. Although the growth of Renvela seems to be fueled by cannibalization of Renagel, Nephrologists expect increases in overall sevelamer share in both dialysis and CKD, as well as increases in Shire's Fosrenol, while continued shifts are expected away from calcium based binders. T...

BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...hate binder market, the introduction of Genzyme's Renvela has given overall sevelamer share a boost compared to the same quarter last year, although most of the ...n the two most frequently prescribed binders among dialysis patients. While sevelamer has the highest share across all types of dialysis units, Shire's Fosrenol ...

BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...enzyme's Renvela is beginning to shift market share in both dialysis and CKD segments. While Renvela has primarily cannibalized Renagel share, overall sevelamer share in both dialysis and CKD has increased compared to the prior year. Despite sevelamer's increased share, for the first time, overall satisfaction...

Genzyme Reports Strong Second-Quarter Growth

...nosis of thyroid cancer and its international adoption is being driven by expansion into new geographic markets. Within the Renal business, sales of sevelamer therapies Renagel(R) (sevelamer hydrochloride) and Renvela grew 16 percent to $168.6 million from $144.9 million in the second quarter last year. Genz...

BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...cal advantages over Renagel and project that Renvela, while primarily cannibalizing share from Renagel, will increase the overall market share for the sevelamer franchise. BioTrends will publish Wave II of LaunchTrends(TM): RENVELA on May 9th. In the management of secondary hyperparathyroidism, while about h...

Genzyme Reports Strong First-Quarter Growth

...also contributing to the product's growth, following the December 2007 U.S. approval for this indication. -- Within the Renal business, sales of sevelamer therapies Renagel(R) (sevelamer hydrochloride) and Renvela grew 23 percent to $168.7 million from $137.4 million in the first quarter last yea...

Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients

...ed risk of cardiovascular morbidity and mortality. sevelamer provides the added benefit of significant LDL cholesterol reduction. sevelamer is the only phosphate binder available that does n...s for Bone Metabolism and Disease in CKD recommend sevelamer as a first-line treatment option to control phosph...

FDA Approves Genzyme's Renvela(TM) for Dialysis Patients

...ed risk of cardiovascular morbidity and mortality. sevelamer provides the added benefit of significant LDL cholesterol reduction. sevelamer is the only phosphate binder available that does n...s for Bone Metabolism and Disease in CKD recommend sevelamer as a first-line treatment option to control phosph...
Other Tags
(Date:9/1/2014)... HealthDay Reporter SATURDAY, ... comparison, an experimental drug was more effective than standard ... patients. According to the study authors, the trial ... the new drug, dubbed LCZ696. In the ... enalapril (Vasotec), either died or were hospitalized due to ...
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 Liver ... the one vital organ that helps the body in barring ... as a store of energy. Liver also plays many important ... cholesterol, iron and glucose. , Many illnesses can affect ... just under the rib cage on the right side of ...
(Date:9/1/2014)... New York, NY (PRWEB) September 01, 2014 ... filings have been added to a federal litigation that ... of South Carolina, Bernstein Liebhard LLP reports. , ... 1,162 claims now filed over the widely-used cholesterol medication ... to the drug. According to claims, Pfizer Inc. failed ...
(Date:9/1/2014)... Dennis Thompson HealthDay ... An experimental Ebola drug previously given to two American aid ... deadly virus in laboratory tests, researchers report. The drug, ... even if they didn,t get the medication until five days ... of Ebola who were days or even hours away from ...
(Date:9/1/2014)... As well as having completed the Non ... counselor certification in Louisiana. , "I have ... program as well as the Counselor training program ... and professionally. I am not only dedicated to ... do so. As a Non Violent Crisis Intervention ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Narconon Louisiana Announces New Certifications For Staff 2
(Date:9/1/2014)... microscopy revealed the presence of tiny blob-like structures that ... still don,t know what they do even though ... be crucial to the life of a cell, and ... In the Journal of Cell Biology , two ... backgrounds, from biophysics to cell biology, to focus their ...
(Date:8/31/2014)... sniffing the highly infectious bacteria C. diff , ... developed by a team at the University of Leicester. ... demonstrated that it is possible to identify the unique ... to rapid diagnosis of the condition., What is more, ... identify different strains of the disease simply from their ...
(Date:8/31/2014)... malaria diagnosis has changed very little. After taking a blood ... a glass slide, stains it with a special dye, and ... the disease. This approach gives an accurate count of how ... of disease severity but is not ideal because there ... the Singapore-MIT Alliance for Research and Technology (SMART) has now ...
Breaking Biology News(10 mins):Scientists call for investigation of mysterious cloud-like collections in cells 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2A new way to diagnose malaria 2A new way to diagnose malaria 3
Other Contents